Routine versus Targeted Viral Load Strategy among Patients Starting Antiretroviral in Hanoi, Vietnam

Todd M Pollack, Hao T Duong, Thuy T Pham, Thang D Nguyen, Howard Libman, Long Ngo, James H McMahon, Julian H Elliott, Cuong D Do, Donn J Colby, Todd M Pollack, Hao T Duong, Thuy T Pham, Thang D Nguyen, Howard Libman, Long Ngo, James H McMahon, Julian H Elliott, Cuong D Do, Donn J Colby

Abstract

Introduction: HIV viral load (VL) testing is recommended by the WHO as the preferred method for monitoring patients on antiretroviral therapy (ART). However, evidence that routine VL (RVL) monitoring improves clinical outcomes is lacking.

Methods: We conducted a prospective, randomized controlled trial of RVL monitoring every six months versus a targeted VL (TVL) strategy (routine CD4 plus VL testing if clinical or immunological failure) in patients starting ART between April 2011 and April 2014 at Bach Mai Hospital in Hanoi. Six hundred and forty-seven subjects were randomized to RVL (n = 305) or TVL monitoring (n = 342) and followed up for three years. Primary endpoints were death or WHO clinical Stage 4 events between six and thirty-six months of ART and rate of virological suppression at three years.

Results: Overall, 37.1% of subjects were female, median age was 33.4 years (IQR: 29.5 to 38.6), and 47% had a CD4 count ≤100 cells/mm3 at time of ART initiation. Approximately 44% of study events (death, LTFU, withdrawal, or Stage 4 event) and 68% of deaths occurred within the first six months of ART. Among patients on ART at six months, death or Stage 4 event occurred in 3.6% of RVL and 3.9% of TVL (p = 0.823). Survival analysis showed no significant difference between the groups (p = 0.825). Viral suppression at 36 months of ART was 97.2% in RVL and 98.9% in TVL (p = 0.206) at a threshold of 400 copies/mL and was 98.0% in RVL and 98.9% in TVL (p = 0.488) at 1000 copies/mL. In ITT analysis, 20.7% in RVL and 21.9% in TVL (p = 0.693) were unsuppressed at 1000 copies/mL.

Conclusions: We found no significant difference in rates of death or Stage 4 events and virological failure in patients with RVL monitoring compared to those monitored with a TVL strategy after three years of follow-up. Viral suppression rates were high overall and there were few study events among patients alive and on ART after six months, limiting the study's power to detect a difference among study arms. Nonetheless, these data suggest that the choice of VL monitoring strategy may have less impact on patient outcomes compared to efforts to reduce early mortality and improve ART retention.

Keywords: ART; HIV; Vietnam; monitoring; randomized controlled trial; viral load.

© 2019 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Figures

Figure 1
Figure 1
Study overview. *Due to entry to jail or drug rehabilitation.
Figure 2
Figure 2
All deaths or new/recurrent Stage 4 events – Kaplan–Meier survival curve.

References

    1. WHO . Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection – recommendations for a public health approach. 2016.
    1. Reynolds SJ, Nakigozi G, Newell K, Ndyanabo A, Galiwongo R, Boaz I, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS. 2009;23:697–700.
    1. Moore DM, Awor A, Downing R, Kaplan J, Montaner JSG, Hancock J, et al. CD4+ T‐cell count monitoring does not accurately identify HIV‐infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;49:477–84.
    1. Kantor R, Diero L, Delong A, Kamle L, Muyonga S, Mambo F, et al. Misclassification of first‐line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource‐limited settings. Clin Infect Dis. 2009;49:454–62.
    1. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS. 2008;22:1971–7.
    1. WHO . Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection – recommendations for a public health approach. 2013.
    1. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second‐line antiretroviral regimen for HIV type 1‐infected patients whose initial regimen of a fixed‐dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis. 2007;44:447–52.
    1. Calmy A, Ford N, Hirschel B, Reynolds SJ, Lynen L, Goemaere E, et al. HIV viral load monitoring in resource‐limited regions: optional or necessary? Clin Infect Dis. 2007;44:128–34.
    1. Kimmel AD, Weinstein MC, Anglaret X, Goldie SJ, Losina E, Yazdanpanah Y, et al. Laboratory monitoring to guide switching antiretroviral therapy in resource‐limited settings: Clinical benefits and cost‐effectiveness. J Acquir Immune Defic Syndr. 2010;54:258–68.
    1. Keiser O, Chi BH, Gsponer T, Boulle A, Orrell C, Phiri S, et al. Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in southern Africa. AIDS. 2011;25:1761–9.
    1. Estill J, Egger M, Johnson LF, Gsponer T, Wandeler G, Davies MA, et al. Monitoring of antiretroviral therapy and mortality in HIV programmes in Malawi, South Africa and Zambia: mathematical modelling study. PLoS One. 2013;8:e57611.
    1. Jourdain G, Le Cœur S, Ngo‐Giang‐Huong N, Traisathit P, Cressey TR, Fregonese F, et al. Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non‐inferiority trial in Thailand. PLoS Med. 2013;10:e1001494.
    1. Okoboi S, Ekwaru PJ, Campbell JD, Egessa A, King R, Bakanda C, et al. No differences in clinical outcomes with the addition of viral load testing to CD4 cell count monitoring among HIV infected participants receiving ART in rural Uganda: long‐term results from the Home Based AIDS Care Project Global health. BMC Public Health. 2016;16:101.
    1. Saag M, Westfall A, Luhanga D, Mulenga P, Chi B, Mulenga L., et al. A cluster randomized trial of routine vs discretionary viral load monitoring among adults starting ART: Zambia. 19th Annual Conference on Retroviruses & Opportunistic Infections. 2012.
    1. Mermin J, Ekwaru JP, Were W, Degerman R, Bunnell R, Kaharuza F, et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial. BMJ. 2011;343:d6792.
    1. WHO . Strategies for optimizing HIV monitoring among adults, children and pregnant women living with HIV receiving antiretroviral therapy: a systematic review. 2013.
    1. MOH . Guidelines for HIV/AIDS diagnosis, treatment, and care. 2009.
    1. MOH . Guidelines for HIV/AIDS diagnosis, treatment, and care. 2011.
    1. MOH . Guidelines for HIV/AIDS diagnosis, treatment, and care. 2015.
    1. Jordan MR, La H, Nguyen HD, Sheehan H, Lien TT, Duong DV, et al. Correlates of HIV‐1 viral suppression in a cohort of HIV‐positive drug users receiving antiretroviral therapy in Hanoi, Vietnam. Int J STD AIDS. 2009;20(6):418–22.
    1. Nguyen DB, Do NT, Shiraishi RW, Le YN, Tran QH, Huu Nguyen H, et al. Outcomes of antiretroviral therapy in Vietnam: results from a national evaluation. PLoS One. 2013;8:e55750.
    1. WHO . Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010.
    1. Roberts T, Cohn J, Bonner K, Hargreaves S. Scale‐up of routine viral load testing in resource‐poor settings: current and future implementation challenges. Clin Infect Dis. 2016;62:1043–8.
    1. Lecher S, Ellenberger D, Kim AA, Fonjungo PN, Agolory S, Borget MY, et al. Scale‐up of HIV viral load monitoring – seven sub‐Saharan African countries. MMWR Morb Mortal Wkly Rep. 2015;64:1287–90.
    1. Rangarajan S, Donn JC, Giang LT, Bui DD, Hung Nguyen H, Tou PB, et al. Factors associated with HIV viral load suppression on antiretroviral therapy in Vietnam. J Virus Erad. 2016;2:94–101.
    1. Tanuma J, Matsumoto S, Haneuse S, Cuong DD, Vu TV, Thuy PTT, et al. Long‐term viral suppression and immune recovery during first‐line antiretroviral therapy: a study of an HIV‐infected adult cohort in Hanoi, Vietnam. J Int AIDS Soc. 2017;20:e25030.
    1. Trinh TT, Montague BT, Flanigan TP, Gerard HM. HIV suppression among patients on treatment in Vietnam: a review of HIV viral load testing in a public urban clinic in Ho Chi Minh City. AIDS Res Treat. 2011;2011:230953.
    1. Cuong DD, Sönnerborg A, Van Tam V, El‐Khatib Z, Santacatterina M, Marrone G, et al. Impact of peer support on virologic failure in HIV‐infected patients on antiretroviral therapy – a cluster randomized controlled trial in Vietnam. BMC Infect Dis. 2016;16:759.
    1. Gupta RK, Hill A, Sawyer AW, Cozzi‐Lepri A, von Wyl V, Yerly S, et al. Virological monitoring and resistance to first‐line highly active antiretroviral therapy in adults infected with HIV‐1 treated under WHO guidelines: a systematic review and meta‐analysis. Lancet Infect Dis. 2009;9:409–17.
    1. Phan V, Thai S, Koole O, Menten J, Meheus F, van Griensven F, et al. Validation of a clinical prediction score to target viral load testing in adults with suspected first‐line treatment failure in resource‐constrained settings. J Acquir Immune Defic Syndr. 2013;62:509–16.
    1. Griensven JV, Phan V, Thai S, Koole O, Lynen L. Simplified clinical prediction scores to target viral load testing in adults with suspected first line treatment failure in Phnom Penh, Cambodia. PLoS One. 2014;1:e87879.
    1. Mungwira RG, Divala TH, Nyirenda OM, Kanjala M, Muwalo F, Mkandawire FA, et al. A targeted approach for routine viral load monitoring in Malawian adults on antiretroviral therapy. Trop Med Int Health. 2018;23(5):526–32.
    1. Ford N, Doherty M. The enduring challenge of advanced HIV infection. N Engl J Med. 2017;377:283–4.
    1. Losina E, Touré H, Uhler LM, Anglaret X, Paltiel AD, Balestre E, et al. Cost‐effectiveness of preventing loss to follow‐up in HIV treatment programs: a Côte d'Ivoire appraisal. PLoS Med. 2009;6:e1000173.
    1. McCreesh N, Andrianakis I, Nsubuga RN, Strong M, Vernon I, McKinley TJ, et al. Universal test, treat, and keep: improving ART retention is key in cost‐effective HIV control in Uganda. BMC Infect Dis. 2017;17:322.
    1. Post FA, Szubert AJ, Prendergast AJ, Johnston V, Lyall H, Fitzgerald F, et al., PSR of Ea mortaLITY in H adults and children starting antiretroviral therapy (REALITY) TT . Causes and timing of mortality and morbidity among late presenters starting antiretroviral therapy in the REALITY trial. Clin Infect Dis. 2018;66:S132–9.
    1. WHO . Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy, July 2017. 2017.
    1. Kerschberger B, Boulle AM, Kranzer K, Hilderbrand K, Schomaker M, Coetzee D, et al. Viral load at 3 months after initiation of antiretroviral therapy is associated with better virological and treatment outcomes than at 6 months. Int. AIDS Conf. Abstr. MOPE144 1720 July 2011. Geneva: International AIDS Society; 2011.
    1. Kanters S, Vitoria M, Doherty M, Socias ME, Ford N, Forrest JI, et al. Comparative efficacy and safety of first‐line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta‐analysis. Lancet HIV. 2016;3:e510–20.
    1. Elliot E, Chirwa M, Boffito M. How recent findings on the pharmacokinetics and pharmacodynamics of integrase inhibitors can inform clinical use. Curr Opin Infect Dis. 2017;30:58–73.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever